Glycorex Transplantation AB (NGM:GTAB B) ROCE %: -37.76% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:GTAB B Glycorex Transplantation AB NGM:GTAB B
61 GF Score
Price kr1.46
GF Value kr1.81
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Glycorex Transplantation AB ROCE %?

Glycorex Transplantation AB NGM:GTAB B -8.75% 61 ROCE % is -37.76% as of Mar. 2026. GuruFocus rates NGM:GTAB B with a GF Score™ of 61/100 and a GF Value™ of kr1.81 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Glycorex Transplantation AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -37.76%.

Glycorex Transplantation AB  (NGM:GTAB B) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Glycorex Transplantation AB ROCE % Related Terms

Glycorex Transplantation AB ROCE % Historical Data

* Premium members only.

The historical data trend for Glycorex Transplantation AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glycorex Transplantation AB ROCE % Chart

Glycorex Transplantation AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.63 -9.82 -45.72 -23.84 -20.03

Glycorex Transplantation AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.10 -9.82 -20.78 -27.28 -37.76
NGM:GTAB B
61GF Score
Glycorex Transplantation AB NGM:GTAB B
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glycorex Transplantation AB ROCE % Calculation

Glycorex Transplantation AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-7.416/( ( (50.304 - 14.181) + (50.793 - 12.868) )/ 2 )
=-7.416/( (36.123+37.925)/ 2 )
=-7.416/37.024
=-20.03 %

Glycorex Transplantation AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-13.632/( ( (50.793 - 12.868) + (47.674 - 13.399) )/ 2 )
=-13.632/( ( 37.925 + 34.275 )/ 2 )
=-13.632/36.1
=-37.76 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -37.76% mean?
Glycorex Transplantation AB (NGM:GTAB B) has a ROCE % of -37.76% as of Mar. 2026.
Is Glycorex Transplantation AB's ROCE % too high?
Glycorex Transplantation AB's current ROCE % is -37.76%. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's ROCE % compare to VRTX and REGN?
Glycorex Transplantation AB's ROCE % of -37.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Glycorex Transplantation AB's current ROCE % is -37.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (NGM:GTAB B) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.81, compared to a current price of kr1.46 — trading 19.3% below its estimated fair value. The current ROCE % is -37.76%. Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Glycorex Transplantation AB (NGM:GTAB B), the current ROCE % is -37.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glycorex Transplantation AB (NGM:GTAB B) Overvalued in 2026?

Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued. The current stock price of kr1.46 is trading 19.3% below its estimated GF Value™ of kr1.81. GuruFocus considers Glycorex Transplantation AB to be Modestly Undervalued.

Key valuation signals for NGM:GTAB B:

  • ROCE %: -37.76%
  • GF Value™: kr1.81 vs. price of kr1.46 (19.3% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the NGM:GTAB B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glycorex Transplantation AB Business Description

Other Exchanges O33:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score

Get the complete analysis for NGM:GTAB B

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.46
Price
kr1.81
GF Value